Compounds > 2,6-dithiopurine
Page last updated: 2024-12-09

2,6-dithiopurine

Description

2,6-dithiopurine: inhibits the binding of a benzo(a)pyrene diol epoxide to DNA in mouse epidermis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1268252
CHEMBL ID1374565
SCHEMBL ID1275415
MeSH IDM0192849

Synonyms (55)

Synonym
AC-17211
2,6-dimercaptopurine
nsc685799
9h-purine-2,6-dithiol
3,7-dihydropurine-2,6-dithione
xanthine, 2,6-dithio-
2,6-dimercapto-7h-purine
nsc15989
nsc-15989
purine-2,6-dithiol
wln: t56 bm dn fn hnj gsh ish
2,6-dithioxanthine
3,7-dihydro-1h-purine-2,6-dithione
2,6-dithiopurine
nsc 15989
1h-purine-2,6-dithione, 3,7-dihydro-
einecs 226-608-8
ai3-52072
5437-25-2
dithioxanthine
3,9-dihydropurine-2,6-dithione
3,9-dihydro-purine-2,6-dithione
nsc-685799
NCGC00161966-01
D2517
STL122222
AKOS005743323
xanthine, dithio-
AKOS006228076
CCG-2315
c5h4n4s2
FT-0635707
AB01320
1h-purine-2,6(3h,9h)-dithione
AKOS015896905
6-sulfanyl-1,9-dihydro-2h-purine-2-thione
STL324264
AKOS022140013
SCHEMBL1275415
AKOS024258160
VQPMXSMUUILNFZ-UHFFFAOYSA-N
2,6-dithioxo-1,2,3,6-tetrahydro-9h-purine
W-105637
7h-purine-2,6-dithiol
CHEMBL1374565
AC-26506
DTXSID00202744
mfcd00022644
2,3,6,9-tetrahydro-1h-purine-2,6-dithione
AS-59715
BCP30962
dithioxanthine;9h-purine-2,6-dithiol
D71101
2.6-dimercaptopurine
CS-W017002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency50.11870.004023.8416100.0000AID485290
thioredoxin reductaseRattus norvegicus (Norway rat)Potency5.01190.100020.879379.4328AID588453
regulator of G-protein signaling 4Homo sapiens (human)Potency89.12510.531815.435837.6858AID504845
chromobox protein homolog 1Homo sapiens (human)Potency25.11890.006026.168889.1251AID540317
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency56.23410.425612.059128.1838AID504891
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency79.43280.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (50.00)18.2507
2000's0 (0.00)29.6817
2010's3 (37.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.57 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uric acid
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.		6.9910uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		1.9910benzoic acids;
sulfonamide		uricosuric drug
acrolein
[no description available]		1.9910enalherbicide;
human xenobiotic metabolite;
toxin
mustard gas
Mustard Gas: Severe irritant and vesicant of skin, eyes, and lungs. It may cause blindness and lethal lung edema and was formerly used as a war gas. The substance has been proposed as a cytostatic and for treatment of psoriasis. It has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP-85-002, 1985) (Merck, 11th ed).. bis(2-chloroethyl) sulfide : An ethyl sulfide that is diethyl sulfide in which a hydrogen from each of the terminal methyl groups is replaced by a chlorine. It is a powerful vesicant regulated under the Chemical Weapons Convention.		7.4720ethyl sulfide;
organochlorine compound		alkylating agent;
carcinogenic agent;
vesicant
2-chloroethyl methyl sulfide
[no description available]		7.0510
2-chloroethyl ethyl sulfide
[no description available]		7.4720
7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide: 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity.		2.3920epoxideintercalator
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		1.9910L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		2.3820nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
tisopurine
tisopurine: 4-thio analog of allopurinol; structure		1.9710pyrazolopyrimidine
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Skin
[description not available]		02.4320
Skin Neoplasms
Tumors or cancer of the SKIN.		02.4320
alpha-Galactosidase A Deficiency
[description not available]		02.1310
Fabry Disease
An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders.		02.1310
Weight Gain
Increase in BODY WEIGHT over existing weight.		01.9810
Disease, Pulmonary
[description not available]		01.9910
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.		01.9910
Lung Diseases
Pathological processes involving any part of the LUNG.		01.9910
chemdatabank.com